JP2006515883A - ２−デオキシグルコースによる癌の処置 - Google Patents

２−デオキシグルコースによる癌の処置 Download PDF

Info

Publication number
JP2006515883A
JP2006515883A JP2006500881A JP2006500881A JP2006515883A JP 2006515883 A JP2006515883 A JP 2006515883A JP 2006500881 A JP2006500881 A JP 2006500881A JP 2006500881 A JP2006500881 A JP 2006500881A JP 2006515883 A JP2006515883 A JP 2006515883A
Authority
JP
Japan
Prior art keywords
cancer
administered
dose
days
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006500881A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006515883A5 (OSRAM
Inventor
ジョージ ティドマーシュ，
Original Assignee
スレッシュオールド ファーマシューティカルズ， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by スレッシュオールド ファーマシューティカルズ， インコーポレイテッド filed Critical スレッシュオールド ファーマシューティカルズ， インコーポレイテッド
Publication of JP2006515883A publication Critical patent/JP2006515883A/ja
Publication of JP2006515883A5 publication Critical patent/JP2006515883A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2006500881A 2003-01-10 2004-01-09 ２−デオキシグルコースによる癌の処置 Pending JP2006515883A (ja)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US43926603P 2003-01-10 2003-01-10
US45884603P 2003-03-28 2003-03-28
US45866503P 2003-03-28 2003-03-28
US46001203P 2003-04-02 2003-04-02
US49616303P 2003-08-18 2003-08-18
PCT/US2004/000530 WO2004062604A2 (en) 2003-01-10 2004-01-09 Treatment of cancer with 2-deoxyglucose

Publications (2)

Publication Number Publication Date
JP2006515883A true JP2006515883A (ja) 2006-06-08
JP2006515883A5 JP2006515883A5 (OSRAM) 2007-02-22

Family

ID=32719656

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006500881A Pending JP2006515883A (ja) 2003-01-10 2004-01-09 ２−デオキシグルコースによる癌の処置

Country Status (11)

Country Link
US (2) US6979675B2 (OSRAM)
EP (1) EP1587519A4 (OSRAM)
JP (1) JP2006515883A (OSRAM)
KR (1) KR20050098244A (OSRAM)
AU (1) AU2004204778B2 (OSRAM)
BR (1) BRPI0406667A (OSRAM)
CA (1) CA2513399A1 (OSRAM)
IL (1) IL169594A0 (OSRAM)
MX (1) MXPA05007382A (OSRAM)
NO (1) NO20053782L (OSRAM)
WO (1) WO2004062604A2 (OSRAM)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008062780A1 (fr) 2006-11-20 2008-05-29 National University Corporation Kagawa University Désoxycétohexose isomérase et procédé permettant de produire le désoxycétohexose et un dérivé correspondant utilisant le désoxycétohexose
US7795227B2 (en) 2004-06-17 2010-09-14 Wisconsin Alumni Research Foundation Compounds and methods for treating seizure disorders
JP2011527678A (ja) * 2008-07-11 2011-11-04 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム 抗癌活性を有する２−デオキシ単糖の新規なアセテート
JP2012516358A (ja) * 2009-01-29 2012-07-19 コー，ヤング，ヒー 癌治療用組成物及び癌治療方法
JP2013508307A (ja) * 2009-10-22 2013-03-07 プロパンク・ピーティーワイ・リミテッド トリプシノーゲンおよび／またはキモトリプシノーゲン、ならびに、セレン化合物、バニロイド化合物および細胞質解糖系還元剤より選択された活性剤を含む癌治療のための医薬組成物。
JP2013515750A (ja) * 2009-12-30 2013-05-09 蘇州天人合生物技術有限公司 ハロゲン化ジデオキシ糖誘導体ならびにその調製方法および応用
WO2019004338A1 (ja) 2017-06-28 2019-01-03 株式会社 先端医療開発 医薬組成物及び腫瘍免疫活性促進剤
US10201554B2 (en) 2013-04-05 2019-02-12 Board Of Regents, The University Of Texas System Esters of 2-deoxy-monosacharides with anti proliferative activity
RU2707554C1 (ru) * 2019-02-27 2019-11-28 Федеральное государственное бюджетное учреждение "Петербургский институт ядерной физики им. Б.П. Константинова Национального исследовательского центра "Курчатовский институт" (НИЦ "Курчатовский институт-ПИЯФ") Композиция, ингибирующая рост и выживаемость опухолевых клеток

Families Citing this family (110)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8563522B2 (en) 1997-07-08 2013-10-22 The Iams Company Method of maintaining and/or attenuating a decline in quality of life
US7381413B1 (en) * 1998-04-17 2008-06-03 University Of Vermont And State Agricultural College Methods and products related to metabolic interactions in disease
EP1205493A1 (en) * 2000-11-14 2002-05-15 ATOFINA Research Polymerisation catalyst systems and their preparation
US7666459B2 (en) * 2001-09-12 2010-02-23 The Procter & Gamble Company Pet food compositions
US7547673B2 (en) * 2001-09-13 2009-06-16 The Johns Hopkins University Therapeutics for cancer using 3-bromopyruvate and other selective inhibitors of ATP production
JP2006515885A (ja) * 2003-01-17 2006-06-08 スレッシュオールド ファーマシューティカルズ， インコーポレイテッド 癌の処置のための併用療法
US8877178B2 (en) 2003-12-19 2014-11-04 The Iams Company Methods of use of probiotic bifidobacteria for companion animals
US20050158294A1 (en) 2003-12-19 2005-07-21 The Procter & Gamble Company Canine probiotic Bifidobacteria pseudolongum
US7510710B2 (en) 2004-01-08 2009-03-31 The Regents Of The University Of Colorado Compositions of UCP inhibitors, Fas antibody, a fatty acid metabolism inhibitor and/or a glucose metabolism inhibitor
US8318683B2 (en) * 2004-02-06 2012-11-27 Threshold Pharmaceuticals, Inc. Anti-cancer therapies
US20090252834A1 (en) * 2004-05-10 2009-10-08 Michael Griffin Hayek Compositions comprising glucose anti-metabolites
US20070292478A1 (en) * 2004-08-30 2007-12-20 Popowski Youri Medical Implant Provided with Inhibitors of Atp Synthesis
US7740875B2 (en) * 2004-10-08 2010-06-22 Mediquest Therapeutics, Inc. Organo-gel formulations for therapeutic applications
US20060078580A1 (en) * 2004-10-08 2006-04-13 Mediquest Therapeutics, Inc. Organo-gel formulations for therapeutic applications
EP1814392A4 (en) * 2004-11-02 2008-06-11 Conforma Therapeutics Corp METHODS AND COMPOSITIONS FOR TREATING CHRONIC LYMPHOCYTIC LEUKEMIA
CN103285395A (zh) * 2005-02-18 2013-09-11 阿布拉科斯生物科学有限公司 治疗剂的组合和给予方式以及联合治疗
US8735394B2 (en) 2005-02-18 2014-05-27 Abraxis Bioscience, Llc Combinations and modes of administration of therapeutic agents and combination therapy
US7208611B2 (en) 2005-02-23 2007-04-24 Xenoport, Inc. Platinum-containing compounds exhibiting cytostatic activity, synthesis and methods of use
WO2006108681A2 (en) 2005-04-15 2006-10-19 Biomac Privatinstitut Für Medizinische Und Zahnmedizinische Forschung, Entwicklung Und Diagnostik Gmbh Substances and pharmaceutical compositions for the inhibition of glyoxalases and their use against bacteria
EP2270131A1 (en) 2005-05-31 2011-01-05 The Iams Company Feline probiotic lactobacilli
PL1885383T3 (pl) 2005-05-31 2017-06-30 Iams Europe B.V. Kocie probiotyczne bifidobakterie
US20060287253A1 (en) * 2005-06-17 2006-12-21 Kriegler Steven M Compounds and methods for treating seizure disorders
EP1902732A4 (en) * 2005-06-24 2009-07-22 Takeda Pharmaceutical PROPHYLACTIC / THERAPEUTIC AGENT AGAINST HER2-EXPRESSIVE CANCER
US20070032383A1 (en) * 2005-07-27 2007-02-08 Newell M K Systems, methods, and compositions for modifying the metabolism of plants and of euucaryotic microbes
US20070134349A1 (en) * 2005-09-19 2007-06-14 Duke University Methods of treating hematological malignancies
US8278349B2 (en) 2005-11-28 2012-10-02 Ramot At Tel-Aviv University Ltd. Cancer treatment using FTS and 2-deoxyglucose
WO2007067516A2 (en) * 2005-12-06 2007-06-14 Duke University Multiple myeloma
US7754693B2 (en) * 2006-02-16 2010-07-13 Young Hee Ko Composition and method for the efficacious and safe administration of halopyruvate for the treatment of cancer
US8324175B2 (en) 2006-02-16 2012-12-04 Young Hee Ko Compositions and methods for the treatment of cancer
MX2008010833A (es) * 2006-02-24 2008-11-12 Univ Texas Compuestos de hexosa para tratar cancer.
WO2007100728A2 (en) * 2006-02-24 2007-09-07 University Of Miami Mannose derivatives for killing tumor cells
WO2009108926A1 (en) * 2008-02-29 2009-09-03 Board Of Regents, The University Of Texas System Inhibitors of glycolysis useful in the treatment of brain tumors
US9149489B2 (en) * 2006-04-27 2015-10-06 Board Of Regents, University Of Texas System Inhibitors of glycolysis useful in the treatment of brain tumors
US20090156660A1 (en) * 2006-05-03 2009-06-18 Michal Svoboda Pharmaceutical composition containing taxane derivative destined for the preparation of an infusion solution, method of preparation thereof and use thereof
WO2008076964A1 (en) * 2006-12-18 2008-06-26 The Johns Hopkins University Therapeutics for cancer using 3-bromopyruvate and other selective inhibitors of atp production
CN101711158A (zh) 2007-02-01 2010-05-19 爱默思公司 使用葡萄糖抗代谢物、鳄梨或鳄梨提取物减轻哺乳动物炎症和应激反应的方法
US8865646B2 (en) * 2007-03-28 2014-10-21 University Of South California Dietary compositions and methods for protection against chemotherapy, radiotherapy, oxidative stress, and aging
ES2891733T3 (es) 2007-03-28 2022-01-31 Univ Southern California Inducción de la resistencia diferencial al estrés y usos de la misma
RU2349271C2 (ru) * 2007-03-29 2009-03-20 ФГУ Ростовский научно-исследовательский онкологический институт Росздрава Способ лечения рака прямой кишки
US8642067B2 (en) 2007-04-02 2014-02-04 Allergen, Inc. Methods and compositions for intraocular administration to treat ocular conditions
WO2008124691A1 (en) * 2007-04-05 2008-10-16 Threshold Pharmaceuticals, Inc. Glufosfamide combination therapy
WO2009102986A1 (en) * 2008-02-15 2009-08-20 Catholic Healthcare West (D/B/A St. Joseph's Hospital And Medical Center) Treatment of adenocarcinoma expressing lkb1 with mtor inhibitor in combination with cox1 inhibitor
US8394377B2 (en) 2008-02-21 2013-03-12 The Regents Of The University Of Colorado Methods for treating cancer using combination therapy
CA2975228C (en) 2008-05-02 2020-07-21 Seattle Genetics, Inc. Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation
US20110183926A1 (en) * 2008-05-23 2011-07-28 University Of Miami Treatment using continuous low dose application of sugar analogs
EP2296679A4 (en) * 2008-05-27 2012-03-21 Oncolytics Biotech Inc SUPPRESSION OF PRODUCTION OF PRO-INFLAMMATORY CYTOKINES DURING ONCOLYTIC REOVIRUS THERAPY
US9771199B2 (en) 2008-07-07 2017-09-26 Mars, Incorporated Probiotic supplement, process for making, and packaging
US9073985B2 (en) 2008-07-14 2015-07-07 The Regents Of The University Of Colorado, A Body Corporate Methods and products for treating proliferative diseases
WO2010019396A1 (en) * 2008-08-13 2010-02-18 Threshold Pharmaceuticals, Inc. Administration of glufosfamide for the treatment of cancer
ES2464729T3 (es) * 2008-08-21 2014-06-03 The Johns Hopkins University Procedimientos y composiciones para la administración de 3-halopiruvato y compuestos relacionados para el tratamiento del cáncer
UA104147C2 (uk) * 2008-09-10 2014-01-10 Новартис Аг Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань
AU2010223919B2 (en) 2009-03-13 2016-03-31 Les Laboratoires Servier Methods and compositions for cell-proliferation-related disorders
NZ597379A (en) 2009-06-29 2014-04-30 Agios Pharmaceuticals Inc Therapeutic compounds and compositions
US10104903B2 (en) 2009-07-31 2018-10-23 Mars, Incorporated Animal food and its appearance
US8450090B2 (en) 2009-10-06 2013-05-28 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods for promoting fatty acid production in plants
CA2793836C (en) 2009-10-21 2020-03-24 Agios Pharmaceuticals, Inc. Methods and compositions for cell-proliferation-related disorders
EP3064595B1 (en) 2009-10-21 2019-02-27 Agios Pharmaceuticals, Inc. Methods for cell-proliferation-related disorders
GB2478556A (en) * 2010-03-09 2011-09-14 Myrovlytis Technology Ventures Ltd A composition for use in the treatment of Birt-Hogg-Dubô sydrome
CA2794147A1 (en) 2010-03-29 2011-10-06 Abraxis Bioscience, Llc Use of a composition comprising nanoparticles comprising a taxane and an albumin to improve uptake of chemotherapeutics by tumors and for treating a cancer that is highly fibrotic and/or has a dense stroma
BR112012024442A2 (pt) 2010-03-29 2017-03-21 Abraxis Bioscience Llc métodos de tratamento de câncer
RU2576609C2 (ru) 2010-06-04 2016-03-10 АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи Способы лечение рака поджелудочной железы
RU2625768C2 (ru) 2010-08-05 2017-07-18 Сиэтл Дженетикс, Инк. Способы ингибирования фукозилирования белков in vivo с использованием аналогов фукозы
RU2013121744A (ru) 2010-10-13 2014-11-20 Мустафа Билгин Али ДЖАМГОЗ Лечение рака/ингибирование метастазирования
WO2012049439A1 (en) * 2010-10-13 2012-04-19 Imperial Innovations Limited Treatment of cancer/inhibition of metastasis
JP2014505058A (ja) * 2011-01-11 2014-02-27 ザ・ユニバーシティ・オブ・テキサス・エム・ディー・アンダーソン・キャンサー 増殖性および炎症性皮膚疾患の治療用単糖ベース化合物
WO2012123774A1 (en) * 2011-03-11 2012-09-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Glycolytic inhibitor with cytotoxic agent for use in the treatment of a cancer
US20120238511A1 (en) * 2011-03-14 2012-09-20 University Of Southern California 2-deoxy-d-glucose formulations for prevention or treatment of neurodegenerative diseases
PH12017501176B1 (en) 2011-05-03 2023-03-08 Agios Pharmaceuticals Inc Pyruvate kinase activators for use in therapy
CN102827073A (zh) 2011-06-17 2012-12-19 安吉奥斯医药品有限公司 治疗活性组合物和它们的使用方法
CN102827170A (zh) 2011-06-17 2012-12-19 安吉奥斯医药品有限公司 治疗活性组合物和它们的使用方法
WO2013017282A1 (en) * 2011-08-02 2013-02-07 Roche Diagnostics Gmbh In vitro tumor metastasis model
KR101900478B1 (ko) * 2011-08-04 2018-09-20 한올바이오파마주식회사 암의 재발 또는 전이의 억제용 약제학적 조성물
AU2013207289B2 (en) 2012-01-06 2017-09-21 Les Laboratoires Servier Therapeutically active compounds and their methods of use
US9474779B2 (en) 2012-01-19 2016-10-25 Agios Pharmaceuticals, Inc. Therapeutically active compositions and their methods of use
WO2013123151A1 (en) * 2012-02-14 2013-08-22 The Wistar Institute Of Anatomy And Biology Methods of controlling tumor bioenergetics networks
AU2013202693B2 (en) * 2012-04-16 2015-01-22 Baxalta GmbH Combination Therapy of Anti-MIF Antibodies and Chemotherapeutics
WO2014031875A1 (en) 2012-08-23 2014-02-27 Seattle Genetics, Inc. Treatment of sickle cell disease and inflammatory conditions
WO2014062511A1 (en) 2012-10-15 2014-04-24 Agios Pharmaceuticals, Inc. Therapeutic compounds and compositions
WO2014072967A1 (en) * 2012-11-12 2014-05-15 Urifer Ltd Drug combination comprising a glycolysis inhibitor and a tyrosine kinase inhibitor
KR101419816B1 (ko) * 2013-01-30 2014-07-17 (주)제욱 상승적 치료 효과를 갖는 비소세포폐암의 예방 또는 치료용 조성물
US9579324B2 (en) 2013-07-11 2017-02-28 Agios Pharmaceuticals, Inc Therapeutically active compounds and their methods of use
WO2015003360A2 (en) 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
WO2015003355A2 (en) 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
CA2917671A1 (en) 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. 2,4-or 4,6-diaminopyrimidine compounds as idh2 mutants inhibitors for the treatment of cancer
US20150031627A1 (en) 2013-07-25 2015-01-29 Agios Pharmaceuticals, Inc Therapeutically active compounds and their methods of use
JP6552509B2 (ja) 2014-01-14 2019-07-31 ザ・ジョンズ・ホプキンス・ユニバーシティー 選択的ａｔｐ阻害剤をカプセル化するシクロデキストリン組成物およびその使用
KR20220070066A (ko) 2014-03-14 2022-05-27 아지오스 파마슈티컬스 아이엔씨. 치료적으로 활성인 화합물의 약제학적 조성물
WO2016065353A1 (en) * 2014-10-24 2016-04-28 University Of Miami Combination therapy with fenofibrate and 2-deoxyglucose or 2-deoxymannose
SI3307271T1 (sl) 2015-06-11 2023-11-30 Agios Pharmaceuticals, Inc. Postopki za uporabo aktivatorjev piruvat kinaze
PT3362065T (pt) 2015-10-15 2024-06-21 Servier Lab Terapia de combinação compreendendo ivosidenib, citarabina e daunorubicina ou idarubicina para o tratamento de leucemia mielóide aguda
US10653710B2 (en) 2015-10-15 2020-05-19 Agios Pharmaceuticals, Inc. Combination therapy for treating malignancies
WO2017079563A1 (en) 2015-11-06 2017-05-11 The Johns Hopkins University Methods of treating liver fibrosis by administering 3-bromopyruvate
HK1259489A1 (zh) 2015-11-12 2019-11-29 普罗潘克股份有限公司 酶原组合物
IL260814B2 (en) 2016-01-29 2023-04-01 Propanc Pty Ltd Cancer treatment
WO2017173360A2 (en) * 2016-03-31 2017-10-05 Stcube, Inc. Combination treatments directed toward programmed death ligand-1 (pd-l1) positive cancers
CN111050764A (zh) 2017-07-21 2020-04-21 巴克老年研究所 β-羟基丁酸酯和丁二醇的S对映异构体及其使用方法
WO2019147503A1 (en) 2018-01-25 2019-08-01 Buck Institute For Research On Aging Synthesis of 3-hydroxybutyryl 3-hydroxybutyrate and related compounds
US11013733B2 (en) 2018-05-16 2021-05-25 Forma Therapeutics, Inc. Inhibiting mutant isocitrate dehydrogenase 1 (mlDH-1)
US11013734B2 (en) 2018-05-16 2021-05-25 Forma Therapeutics, Inc. Treating patients harboring an isocitrate dehydrogenase-1 (IDH-1) mutation
PT3720442T (pt) 2018-05-16 2023-03-13 Forma Therapeutics Inc Inibição de idh-1 mutante
US11311527B2 (en) 2018-05-16 2022-04-26 Forma Therapeutics, Inc. Inhibiting mutant isocitrate dehydrogenase 1 (mIDH-1)
WO2019222551A1 (en) 2018-05-16 2019-11-21 Forma Therapeutics, Inc. Solid forms of ((s)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile
US10980788B2 (en) 2018-06-08 2021-04-20 Agios Pharmaceuticals, Inc. Therapy for treating malignancies
CA3170872A1 (en) 2020-03-16 2021-09-23 Board Of Regents, The University Of Texas System Method of treating viral infections with hexose type monosaccharides and analogs thereof
WO2021211609A1 (en) * 2020-04-16 2021-10-21 Buck Institute For Research On Aging Treatment of viral pathologies with exogenous ketones
KR20230131847A (ko) * 2020-12-14 2023-09-14 트림 바이오테크, 에스. 엘. 암 면역치료를 위한 박테리아를 포함하는 조성물
WO2023062516A1 (en) * 2021-10-11 2023-04-20 Exploration Invest Pte Ltd 2-deoxy-d-glucose for use in disease therapy
CN114617876B (zh) * 2022-01-28 2023-04-07 四川大学华西医院 一种抗肿瘤联合用药物
KR20240038394A (ko) 2022-09-16 2024-03-25 이화여자대학교 산학협력단 해당과정 억제제 및 미토콘드리아 기능 억제제를 포함하는 암의 예방 또는 치료용 약학적 조성물
EP4582080A1 (en) 2024-01-02 2025-07-09 G.ST Antivirals GmbH Dispenser for mucosal administration comprising 2-deoxy-glucose or analogues thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06511041A (ja) * 1992-09-08 1994-12-08 ラッキー・リミテッド 熱可塑性樹脂用光沢低減剤の製造方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS606630B2 (ja) 1977-09-07 1985-02-19 藤沢薬品工業株式会社 ２―デオキシ―ｄ―グルコースの製造法
US4315001A (en) * 1979-08-17 1982-02-09 Blough Herbert A 2-Deoxy glucose as an antiviral agent against herpes simplex
US5185325A (en) * 1988-06-23 1993-02-09 Chesebrough-Pond's Usa Co., Division Of Conopco, Inc. Cosmetic composition
EP0565785A1 (en) 1992-04-07 1993-10-20 Harry H. Leveen Use of glucose transport inhibitors for the treatment for acne
US5591429A (en) * 1993-07-26 1997-01-07 The United States Of America As Represented By The Secretary Of Agriculture Composition containing 2-deoxy-D-glucose and Candida saitoana and a method of use for the biological control of postharvest diseases
US5643883A (en) * 1995-01-19 1997-07-01 Uab Research Foundation Glucose-6-phosphate uptake inhibitors and novel uses thereof
DE19524515A1 (de) * 1995-07-05 1997-01-09 Deutsches Krebsforsch Saccharid-Konjugate
US5652273A (en) * 1995-11-30 1997-07-29 Henry; James Reduction of hair growth
US5565434A (en) * 1996-02-23 1996-10-15 University Of Iowa Research Foundation Hexose and pentose prodrugs of ethacrynic acid
US5958892A (en) * 1996-07-30 1999-09-28 Board Of Regents, The University Of Texas System 2-methoxyestradiol-induced apoptosis in cancer cells
US20020035071A1 (en) * 1997-07-08 2002-03-21 Josef Pitha Mimicking the metabolic effects of caloric restriction by administration of glucose antimetabolites
GR1003713B (el) 1998-03-20 2001-11-07 Δεσοξυσακχαρα ως αντικαρκινικοι αναχαιτιστικοι παραγοντες.
US20030072814A1 (en) * 1999-12-16 2003-04-17 Maibach Howard I. Topical pharmaceutical composition for the treatment of warts
US6670330B1 (en) 2000-05-01 2003-12-30 Theodore J. Lampidis Cancer chemotherapy with 2-deoxy-D-glucose
US6974664B2 (en) * 2000-05-12 2005-12-13 The Board Of Trustees Of The Leland Stanford University Screening method for cancer therapeutics and stable antitumor drug
WO2002058741A2 (en) 2000-12-18 2002-08-01 Alex Wah Hin Yeung Treatment of cancer with positron-emitting radiopharmaceuticals
US6661410B2 (en) * 2001-09-07 2003-12-09 Microsoft Corporation Capacitive sensing and data input device power management

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06511041A (ja) * 1992-09-08 1994-12-08 ラッキー・リミテッド 熱可塑性樹脂用光沢低減剤の製造方法

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7795227B2 (en) 2004-06-17 2010-09-14 Wisconsin Alumni Research Foundation Compounds and methods for treating seizure disorders
US8389248B2 (en) 2006-11-20 2013-03-05 National University Corporation Kagawa University Deoxyketohexose isomerase and method for producing deoxyhexose and derivative thereof using same
WO2008062780A1 (fr) 2006-11-20 2008-05-29 National University Corporation Kagawa University Désoxycétohexose isomérase et procédé permettant de produire le désoxycétohexose et un dérivé correspondant utilisant le désoxycétohexose
JP2011527678A (ja) * 2008-07-11 2011-11-04 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム 抗癌活性を有する２−デオキシ単糖の新規なアセテート
JP2015180680A (ja) * 2009-01-29 2015-10-15 コー，ヤング，ヒー 癌治療用組成物及び癌治療方法
JP2012516358A (ja) * 2009-01-29 2012-07-19 コー，ヤング，ヒー 癌治療用組成物及び癌治療方法
JP2013508307A (ja) * 2009-10-22 2013-03-07 プロパンク・ピーティーワイ・リミテッド トリプシノーゲンおよび／またはキモトリプシノーゲン、ならびに、セレン化合物、バニロイド化合物および細胞質解糖系還元剤より選択された活性剤を含む癌治療のための医薬組成物。
JP2013515750A (ja) * 2009-12-30 2013-05-09 蘇州天人合生物技術有限公司 ハロゲン化ジデオキシ糖誘導体ならびにその調製方法および応用
US10201554B2 (en) 2013-04-05 2019-02-12 Board Of Regents, The University Of Texas System Esters of 2-deoxy-monosacharides with anti proliferative activity
US11026960B2 (en) 2013-04-05 2021-06-08 Board Of Regents, The University Of Texas System Esters of 2-deoxy-monosaccharides with anti proliferative activity
US11925654B2 (en) 2013-04-05 2024-03-12 Board Of Regents, The University Of Texas System Esters of 2-deoxy-monosaccharides with anti proliferative activity
WO2019004338A1 (ja) 2017-06-28 2019-01-03 株式会社 先端医療開発 医薬組成物及び腫瘍免疫活性促進剤
KR20200018634A (ko) 2017-06-28 2020-02-19 가부시키가이샤 센탄이료카이하츠 의약조성물 및 종양면역활성 촉진제
RU2707554C1 (ru) * 2019-02-27 2019-11-28 Федеральное государственное бюджетное учреждение "Петербургский институт ядерной физики им. Б.П. Константинова Национального исследовательского центра "Курчатовский институт" (НИЦ "Курчатовский институт-ПИЯФ") Композиция, ингибирующая рост и выживаемость опухолевых клеток

Also Published As

Publication number Publication date
EP1587519A4 (en) 2006-05-31
MXPA05007382A (es) 2005-11-23
AU2004204778A1 (en) 2004-07-29
US20040167079A1 (en) 2004-08-26
US6979675B2 (en) 2005-12-27
AU2004204778B2 (en) 2008-05-22
US20050245462A1 (en) 2005-11-03
IL169594A0 (en) 2007-07-04
CA2513399A1 (en) 2004-07-29
NO20053782L (no) 2005-09-27
EP1587519A2 (en) 2005-10-26
NO20053782D0 (no) 2005-08-09
BRPI0406667A (pt) 2005-12-20
WO2004062604A2 (en) 2004-07-29
WO2004062604A3 (en) 2005-05-26
KR20050098244A (ko) 2005-10-11

Similar Documents

Publication Publication Date Title
US6979675B2 (en) Treatment of cancer with 2-deoxyglucose
RU2757373C2 (ru) Комбинированная терапия противоопухолевым алкалоидом
Koizumi et al. Phase II study of S-1, a novel oral derivative of 5-fluorouracil, in advanced gastric cancer
ES2258566T3 (es) Combinaciones de farmacos (por ejemplo, clorpromacina y pentamidina) para el tratamiento de trastornos neoplasicos.
EP1383490B1 (en) Combination of an epothilone analog and chemotherapeutic agents for the treatment of proliferative diseases
US20060276527A1 (en) Combination therapies for the treatment of cancer
EP2034835B1 (en) Non-toxic anti-cancer drug combining ascorbate, magnesium and a naphthoquinone
US12102613B2 (en) Compositions, methods, systems and/or kits for preventing and/or treating neoplasms
EP2575783B1 (en) Methods and compositions for oral pharmaceutical therapy
US7705049B2 (en) Methods for treating non-melanoma cancers with PABA
TWI468161B (zh) 組合藥劑之醫藥產品、試劑及用途
EP4393493A1 (en) Parp inhibitor-resistant patient treated with th-302
JP2019501184A (ja) 鉄化合物及びシトレート化合物を用いる併用療法
Pratt et al. Phase II study of 5‐fluorouracil/leucovorin for pediatric patients with malignant solid tumors
CN1771043A (zh) 利用2－脱氧葡萄糖治疗癌症
US9913816B2 (en) Method for applying metformin and sodium butyrate in K-ras mutation cancer treatment
US20070269531A1 (en) Non-Steroid Anti-Inflammatory Agents with Vitamins, Minerals, and Dietary Supplements for the Prevention and Treatment of Primary, Secondary and Tertiary Cancer
US20200268665A1 (en) Compositions and methods for cancer treatment
CN101437523A (zh) 利用2-脱氧半乳糖治疗癌症
TW202434219A (zh) 使用乏氧激活化合物治療對parp抑制劑耐藥的患者的藥物及其製藥用途
KR20100058662A (ko) 개에게서 림프종을 치료하기 위한 이다루비신
工藤昌尚 et al. Effects of combined treatment with micelle-incorporated cisplatinum (NC-6004) and S-1 on human gastric cancer xenografts
JP2019131559A (ja) 頭頚部がんの処置または予防において使用されるｐｉ３キナーゼ阻害剤とパクリタキセルの組合せ
HK1060843B (en) Combination of an epothilone analog and chemotherapeutic agents for the treatment of proliferative diseases
WO2005120521A2 (en) Methods of treating cancer with 8-chloro-adenosine

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070105

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070105

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100622

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20101207